Interviews

In this Migraine Science Collaborative interview, Verdi discusses building upon successful volunteer-led advocacy efforts, the need for headache-specific legislation, and why it is important to be proactive at the policy level to make positive changes for those living with migraine and headache disorders.

Philip Holland discusses his path to the migraine field, some of the projects he’s working on now, and his interests outside of science.

In this MSC interview, Dr. Ailani discusses her research on situational prevention of migraine, and her role in shaping the American Headache Society’s Research Priorities Initiative.

In this MSC interview, Moises Dominguez discusses the historical lack of structured headache medicine curricula in medical education, how social media and artificial intelligence can help make learning easier, and why he’s optimistic about the future of headache education.

In this Migraine Science Collaborative interview, Dr. Woldeamanuel talks about the hidden complexities of the circadian system and shares his experience on this new migraine research frontier.

In this Migraine Science Collaborative interview, Dr. Hamid Djalilian discusses his interest in vestibular migraine, the mis- and under-diagnosis of this condition, and what he would like people to know about it.

In this Migraine Science Collaborative interview, Dr. Christina Szperka discusses how she got started in the field, the peculiarities of pediatric migraine, and her work on new daily persistent headache (NDPH).

In this Migraine Science Collaborative interview, Mandee Schaub discusses her research, her advocacy efforts, and much more.

In this MSC interview, Dr. Burish discusses his journey to the headache field, the features and treatment of cluster headache, key unknowns about this condition, and more.

In this Migraine Science Collaborative interview, Dr. Lipton discusses the questions he’s most interested in as a headache researcher, key results from past migraine clinical trials, what the future may look like for additional trials, and more.